Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
A Pilot, Open-label, Multicenter Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
Sponsor: Celldex Therapeutics
Terminated
Portfolio prioritization due to slow enrollment and variable spectrum of potential complement abnormalities in DDD patients.
Other terminated trials from Celldex Therapeutics
Listed as NCT01791686, this PHASE1 trial focuses on C3 Glomerulonephritis and Dense Deposit Disease and remains terminated or withdrawn. Sponsored by Celldex Therapeutics, it has been updated 10 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE1
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE1
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE1
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Jan 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celldex Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .